Buprenorphine Treatment for Pregnant Women Linked to Superior Infant Outcomes and Stable Long-Term Child Development

Stanford and Harvard study confirms buprenorphine leads to better infant health outcomes and comparable long-term development versus methadone.

By: AXL Media

Published: Apr 16, 2026, 7:32 AM EDT

Source: Information for this report was sourced from EurekAlert

A Comparative Analysis of Opioid Agonist Therapies

Medical researchers have identified significant health advantages for infants when buprenorphine is utilized as the primary treatment for maternal opioid use disorder. Drawing from a massive database of over 30,000 pregnant women enrolled in public insurance, the study highlights a critical shift in how clinicians might approach addiction recovery during pregnancy. The data suggests that while both buprenorphine and methadone serve to reduce cravings and prevent withdrawal, the specific choice of medication can have a measurable impact on the immediate health of the newborn.

Quantifying the Neonatal Health Advantage

The research indicates that infants exposed to buprenorphine in the final 30 days of pregnancy were significantly less likely to suffer from neonatal abstinence syndrome compared to those exposed to methadone. Specifically, the syndrome occurred in 52 percent of the buprenorphine group versus nearly 70 percent in the methadone group. According to Dr. Brian Bateman, Chair of the Department of Anesthesiology, Perioperative, and Pain Medicine at Stanford, the data provides a clear suggestion of causal effects rather than mere coincidental patient characteristics.

Physical Development and Birth Weight Benchmarks

Beyond withdrawal symptoms, the study found that buprenorphine exposure was associated with healthier birth weights and lower rates of preterm birth. Infants in the methadone group experienced abnormally low birth weights at a rate of 14.9 percent, nearly double the 8.3 percent seen in the buprenorphine group. These physical health markers are essential indicators of long-term vitality, suggesting that buprenorphine may offer a more stable environment for fetal development during the critical early and late stages of gestation.